[
  {
    "ts": null,
    "headline": "Wall Street Meets the World Bank: Inside the $510M CLO Deal Shaking Up Global Finance",
    "summary": "The World Bank's first-ever securitization flips the script on emerging market funding--with Goldman Sachs in the cockpit.",
    "url": "https://finnhub.io/api/news?id=7105c8c0dd375d0ae21cad1365deb6588a5f4af13d95cc73c9d99523fe332145",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756494443,
      "headline": "Wall Street Meets the World Bank: Inside the $510M CLO Deal Shaking Up Global Finance",
      "id": 136575492,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCO",
      "source": "Yahoo",
      "summary": "The World Bank's first-ever securitization flips the script on emerging market funding--with Goldman Sachs in the cockpit.",
      "url": "https://finnhub.io/api/news?id=7105c8c0dd375d0ae21cad1365deb6588a5f4af13d95cc73c9d99523fe332145"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin",
    "summary": "AbbVie's strong financial results for the second quarter of 2025 were ensured by its two superstars, Rinvoq and Skyrizi. Click here to read my latest analysis.",
    "url": "https://finnhub.io/api/news?id=cd5b0e7f7073f7c6b99befc729473d98b794028f55711773ec7140c00fc76cbf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756471054,
      "headline": "AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin",
      "id": 136571810,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1823932204/image_1823932204.jpg?io=getty-c-w1536",
      "related": "MCO",
      "source": "SeekingAlpha",
      "summary": "AbbVie's strong financial results for the second quarter of 2025 were ensured by its two superstars, Rinvoq and Skyrizi. Click here to read my latest analysis.",
      "url": "https://finnhub.io/api/news?id=cd5b0e7f7073f7c6b99befc729473d98b794028f55711773ec7140c00fc76cbf"
    }
  },
  {
    "ts": null,
    "headline": "BMO Capital Keeps Moody’s (MCO) at Market Perform, Raises PT to $534",
    "summary": "Moody’s Corporation (NYSE:MCO) is one of the best long-term stocks to invest in according to Warren Buffett. On August 22, BMO Capital reiterated a “Market Perform” rating for Moody’s with a price target of $534. The decision follows leadership changes at Moody’s. Stephen Tulenko, President of Moody’s Analytics, a division of Moody’s Corporation, announced his […]",
    "url": "https://finnhub.io/api/news?id=5387aa76416ab443d8257620618ff4124415df9886b1beba3e9ccdda60390335",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756441996,
      "headline": "BMO Capital Keeps Moody’s (MCO) at Market Perform, Raises PT to $534",
      "id": 136569446,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCO",
      "source": "Yahoo",
      "summary": "Moody’s Corporation (NYSE:MCO) is one of the best long-term stocks to invest in according to Warren Buffett. On August 22, BMO Capital reiterated a “Market Perform” rating for Moody’s with a price target of $534. The decision follows leadership changes at Moody’s. Stephen Tulenko, President of Moody’s Analytics, a division of Moody’s Corporation, announced his […]",
      "url": "https://finnhub.io/api/news?id=5387aa76416ab443d8257620618ff4124415df9886b1beba3e9ccdda60390335"
    }
  }
]